SCHEMBL5664136

SCHEMBL5664136

Cc1ccccc1C(=O)OCC=O

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TSHR P16473 6/20 0.53
CYP3A4 P08684 1/20 0.53
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
ADRB2 P07550 2/20 0.49
ADRB1 P08588 2/20 0.49
ADRB3 P13945 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.48
L3MBTL1 Q9Y468 3/20 0.48
ALDH1A1 P00352 5/20 0.46
HSD17B10 Q99714 3/20 0.46
NPC1 O15118 3/20 0.45
TDP1 Q9NUW8 2/20 0.45
RAB9A P51151 2/20 0.44
CASP1 P29466 1/20 0.44
CASP7 P55210 1/20 0.44
GAA P10253 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6423366 0.86 KMT2A (0.52) TSHRCYP3A4MEN1KMT2ASMN1; SMN2
SCHEMBL8238432 0.84 CYP3A4 (0.77) TSHRCYP3A4MEN1KMT2AADRB2
SCHEMBL29535471 0.81 TSHR (0.80) TSHRCYP3A4MEN1KMT2AADRB2
SCHEMBL1569293 0.81 TSHR (0.80) TSHRCYP3A4MEN1KMT2AADRB2
SCHEMBL17797782 0.81 TSHR (0.66) TSHRCYP3A4MEN1KMT2AADRB2
SCHEMBL24938449 0.81 TSHR (0.52) TSHRCYP3A4L3MBTL1ALDH1A1HSD17B10
SCHEMBL3487724 0.80 CA12 (0.47) TSHRCYP3A4MEN1KMT2ASMN1; SMN2
SCHEMBL1347940 0.80 ALDH1A1 (0.61) TSHRCYP3A4SMN1; SMN2L3MBTL1ALDH1A1
SCHEMBL7933514 0.79 TSHR (0.59) TSHRCYP3A4MEN1KMT2AADRB2
SCHEMBL27501881 0.79 TSHR (0.77) TSHRCYP3A4MEN1KMT2AADRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1461041-A4 PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES PHARMASSET LTD (BB) 2006-03-29 EP claimed
EP-1461041-A2 PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES Pharmasset Ltd. (BB) 2004-09-29 EP claimed
US-20030162992-A1 Reacting a 2,2-dialkoxyethyl halide with an appropriate carboxylate compound to obtain acetal compound; hydrolyzing the acetal to form the alpha -acyloxyacetaldehyde PHARMASSET, INC. 2003-08-28 US claimed
WO-2003051298-A2 PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES PHARMASSET LTD. (BB) 2003-06-26 WO claimed
EP-1461041-A4 PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES PHARMASSET LTD (BB) 2006-03-29 EP disclosed
EP-1461041-A2 PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES Pharmasset Ltd. (BB) 2004-09-29 EP disclosed
US-20030162992-A1 Reacting a 2,2-dialkoxyethyl halide with an appropriate carboxylate compound to obtain acetal compound; hydrolyzing the acetal to form the alpha -acyloxyacetaldehyde PHARMASSET, INC. 2003-08-28 US disclosed
WO-2003051298-A2 PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES PHARMASSET LTD. (BB) 2003-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030162992-A1 Reacting a 2,2-dialkoxyethyl halide with an appropriate carboxylate compound to obtain acetal compound; hydrolyzing the acetal to form the alpha -acyloxyacetaldehyde DERA, DPYD, DHPS TSHR 3766/4885CYP3A4 1525/4885MEN1 2878/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.